
| Pair Name | Lupeol, Paclitaxel | ||
| Phytochemical Name | Lupeol (PubChem CID: 259846 ) | ||
| Anticancer drug Name | Paclitaxel (PubChem CID: 36314 ) | ||
| Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
| Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
||
| Drug Name | Paclitaxel |
| Adverse Reactions | Bronchospasmodic dyspnoea, hypotension, peripheral neuropathy and bone, joint and muscle aches and pains. This was inferred cold nature anticancer drug. |
| Recommendations | Hot: Dimocarpus longan; Terminalia chebula; Astragalus membranaceus; Lycopodium japonicum |
| Reference | Malignant tumors in the era of immunotherapy based on traditional Chinese medicine's "cold and hot theory" Construction of integrated traditional Chinese and Western medicine treatment paradigm[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine,2023,32(12):1712-1716. DOI:10.3969/j.issn.1008-8849.2023.12.022. ref_link |
| Pair Name | Lupeol, Paclitaxel | |||
| Disease Info | [ICD-11: 2B66.0] | Oral squamous cell carcinoma | Investigative | |
| Biological Phenomena | Induction-->Vasculogenic mimicry | |||
| Gene Regulation | Down-regulation | Expression | HIF1A | hsa3091 |
| Down-regulation | Expression | CDH5 | hsa1003 | |
| Down-regulation | Expression | EPHA2 | hsa1969 | |
| Down-regulation | Expression | MMP2 | hsa4313 | |
| Up-regulation | Expression | BAX | hsa581 | |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Expression | CDH1 | hsa999 | |
| Down-regulation | Expression | VIM | hsa7431 | |
| Down-regulation | Expression | SNAI1 | hsa6615 | |
| Down-regulation | Expression | TWIST1 | hsa7291 | |
| Down-regulation | Expression | PROM1 | hsa8842 | |
| In Vitro Model | UPCI-SCC-154 | Tongue squamous cell carcinoma | Homo sapiens (Human) | CVCL_2230 |
| UPCI-SCC-090 | Tongue squamous cell carcinoma | Homo sapiens (Human) | CVCL_1899 | |
| Result | Our findings elucidated mechanistic underpinning of hypoxia induced Laminin-5γ2 driven VM formation highlighting that Lupeol-Paclitaxel combination may serve as novel therapeutic intervention in perturbation of VM in human OSCC. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Lupeol and Paclitaxel cooperate in hindering hypoxia induced vasculogenic mimicry via suppression of HIF-1α-EphA2-Laminin-5γ2 network in human oral cancer. J Cell Commun Signal. 2023 Sep;17(3):591-608. doi: 10.1007/s12079-022-00693-z. | Click |